Patient characteristics
death, Cardiac and gastric fundus
ONCOLOGY, DISEASE PROGRESSION, LIVER, PERITONEUM
In the first stage, 2 in 8 patients had a PR, and 22 patients were enrolled in the second stage. The baseline characteristics of 30 patients are summarized in Table 
Demographics and baseline characteristics Male Female23(76.7)7(23.3) 0 1 24(13.3)25(83.3)1(3.3) Lower esophagus Cardiac and gastric fundus Gastric body Gastric antrum1(3.3)7(23.3)13(43.3)9(30.0) G1 G2 G30(0)5(16.7)25(83.3) Intestinal type Diffuse type Mixed type or unknown9(30.0)14(46.7)7(23.3) Lymph node Peritoneum Liver Bone Lung19(63.3)9(30.0)8(26.7)2(6.7)1(3.3) First-line Second-line Platinum and Fluorouracil Taxanes25(83.3)5(16.7)29(96.7)7(23.3) MMR deficient MMR proficient0(0)30(100.0) 0 1+ 2+/FISH*(-)22(73.3)4(13.3)4(13.3) Negative Positive30(100.0)0(0)*ECOG PS: Eastern Cooperative Oncology Group Performance StatusMMR: Mismatch RepairMSI: Microsatellite InstabilityHER2: Human Epidermal Growth Factor Receptor 2FISH: Fluorescence in Situ HybridizationEBER: Epstein-Barr virus-encoded RNAAt the data cutoff (March 19, 2022), the median follow-up duration was 12.3 months. 21 patients discontinued this protocol treatment due to disease progression or death, 2 patients due to consent withdraw, and 6 patients dropped out of the study after treatment was interrupted by the COVID-19 for more than 6 weeks. The flowchart of the study is shown in Fig. 
The flowchart of the study